ESR1 and triple-negative breast carcinoma: Indeed, low ER and MAPT mRNA expression were strongly predictive of sensitivity to ixabepilone in the neo-adjuvant setting [43], while ixabepilone seems to benefit patients with triple-negative breast cancer [44].